JESSICA LAURINO: Open Payments
NPI 1609127299 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$877 in 50 payments from 12 companies in 2025. Trend: 2023 $1,438 · 2024 $838 · 2025 $877
Food & beverage: $877
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $267 |
| Ardelyx, Inc. | 6 | $168 |
| PFIZER INC. | 11 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Ipsen Biopharmaceuticals, Inc | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| Janssen Biotech, Inc. | 1 | $28 |
| GENZYME CORPORATION | 1 | $21 |
| Braintree Laboratories, Inc. | 1 | $20 |
Products named: IBSRELA, RINVOQ, XELJANZ, SKYRIZI, ENTYVIO, VELSIPITY, IQIRVO, LINZESS.
Industry payments across AZ — which companies pay providers there.
